Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 8,141 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Terminated No phase listed Observational

CT-Based Changes in Bone and Marrow Among Patients on Oral Steroids

NCT04518722
View directory record Official record
Conditions
Asthma, Bone Density, Low, Oral Steroid-Dependent Asthma (Disorder)
Interventions
CT Scan, DXA Scan, Steroid Intake Questionnaire
Radiation · Other
Lead sponsor
University of Iowa
Other
Eligibility
25 Years to 45 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Not applicable Interventional

Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy

NCT05793151
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oral Cavity Cancer, Larynx Cancer
Interventions
ENDURE
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
St Louis, Missouri • Durham, North Carolina • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

AlmegaPL CV Health Open Label Study

NCT05267301
View directory record Official record
Conditions
Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions
AlmegaPL (FDA NDIN # 826)
Dietary Supplement
Lead sponsor
Qualitas Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Tempe, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 21, 2026, 8:01 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

NCT06428630
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Reaction
Interventions
dexamethasone oral rinse
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Quantitative Genioglossal Muscle Strength in Obstructive Sleep Apnea (OSAS)

NCT02695667
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
20 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Results available

2-Week Study In People With Nonalcoholic Fatty Liver Disease

NCT03513588
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Placebo, PF-06865571
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
6
States / cities
Anaheim, California • New Haven, Connecticut • South Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional

Study of the Glutaminase Inhibitor CB-839 in Leukemia

NCT02071927
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL)
Interventions
CB-839, CB-Aza
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 2 Interventional

Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer

NCT06627270
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma, Oral Cancer, Head and Neck Cancer, Head and Neck Carcinoma
Interventions
Metronidazole, Chlorhexidine
Drug · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 2 Interventional

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

NCT06671054
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
AP1189, 40 mg, AP1189, 70 mg, AP1189, 100 mg, AP1189 matching placebo
Drug
Lead sponsor
SynAct Pharma Aps
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Cutler Bay, Florida • Miami, Florida • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

NCT01260922
View directory record Official record
Conditions
Healthy
Interventions
Donepezil Hydrochloride, Aricept®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 21, 2011 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis

NCT04034251
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastric Cancer, Esophagogastric Junction, Peritoneal Carcinomatosis
Interventions
Paclitaxel, Capecitabine, BardPort Titanium Implanted Port with Peritoneal Catheter
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00246753
View directory record Official record
Conditions
Prostate Cancer
Interventions
lapatinib ditosylate
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

Oral CXA-10 in Pulmonary Arterial Hypertension

NCT04125745
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
CXA-10
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 21, 2026, 8:01 AM EDT
Not yet recruiting No phase listed Observational

Unmasking Diabetes in Dialysis With Continuous Glucose Monitoring

NCT07880795
View directory record Official record
Conditions
End Stage Kidney Disease (ESKD), Hyperglycaemia, Diabetes
Interventions
Continuous Glucose Monitoring (CGM)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 2 Interventional

Study of CEP-701 in Treatment of Prostate Cancer

NCT00081601
View directory record Official record
Conditions
Prostate Cancer
Interventions
CEP-701
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2012 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

NCT02454712
View directory record Official record
Conditions
Healthy
Interventions
PF614, Oxycodone extended-release, Naltrexone Hydrochloride
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00678210
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Oceanside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

NCT00159913
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Children
Interventions
Sildenafil citrate, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 8:01 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Surzetoclax, Daratumumab, Dexamethasone, Pomalidomide, Etentamig
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 21, 2026, 8:01 AM EDT
Completed Phase 4 Interventional Results available

Study in Adolescents With Schizophrenia or Bipolar Disorder

NCT00982020
View directory record Official record
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Drug · Behavioral
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 17 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Lauderhill, Florida • Bloomfield Hills, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated Phase 1 Interventional Results available

Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma

NCT02034123
View directory record Official record
Conditions
Carcinoma, Small Cell
Interventions
GSK2879552
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 21, 2026, 8:01 AM EDT
Terminated Phase 2 Interventional Results available

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

NCT00114959
View directory record Official record
Conditions
Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
Interventions
Homoharringtonine, Imatinib Mesylate
Drug
Lead sponsor
ChemGenex Pharmaceuticals
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2015 · Synced Oct 21, 2026, 8:01 AM EDT
Completed No phase listed Observational

Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception

NCT01963962
View directory record Official record
Conditions
Emergency Contraception
Interventions
Copper IUD, Levonorgestrel IUD
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 21, 2026, 8:01 AM EDT